EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development

Kyle W Cuklanz iD, Abigail Stein iD, Virginie-Anne Chouinard, Dost Ongur, Fei Du iD

Science Advances · 2026-02-20 · 12 (8)

DOI: 10.1126/sciadv.aea9014 ↗

At a glance

Übersichtsarbeit in Science Advances, published on 2026-02-20. Written by Kyle W Cuklanz and 4 co-authors. Institution: Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, USA. Major MEDLINE topics: Biomarkers, Mental Disorders. Cited 5 times so far (Crossref); 153 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIMH NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Redox dysregulation, characterized by an imbalance in the NAD + [nicotinamide adenine dinucleotide (oxidized form)]/NADH (reduced form of NAD + ) ratio, is implicated in neurodegenerative and psychiatric disorders such as Alzheimer’s disease and schizophrenia. This imbalance contributes to mitochondrial dysregulation, oxidative stress, and inflammation. Despite promising preclinical studies supporting therapeutic strategies aimed at restoring redox balance and thereby rescuing brain bioenergetic deficits, clinical outcomes and efficacy remain limited. Progress has been hindered by the incomplete understanding of NAD + subcellular cycling, as well as a lack of in vivo biomarkers measuring target engagement of redox status and mitochondrial function. Thus, this review examines molecular mechanisms of NAD (nicotinamide adenine dinucleotide)–related bioenergetic deficits, current and emerging NAD-targeted therapies, and recent advances in the development of neuroimaging biomarkers, emphasizing personalized and mechanism-driven approaches.

Subjects

MeSH terms (MEDLINE)

BiomarkersMental DisordersHumansOxidation-ReductionOxidative StressAnimalsMitochondriaNADAlzheimer DiseaseEnergy MetabolismSchizophrenia

Substances

BiomarkersNAD

Authors and institutions

  • Psychotic Disorders Division, McLean Hospital, Belmont, MA 02478, USA.
  • McLean Imaging Center, McLean Hospital, Belmont, MA 02478, USA.
  • Harvard Medical School, Boston, MA, 02115, USA.
  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA.

ORCID profiles: Kyle W Cuklanz, Abigail Stein, Fei Du

Funding

  • NIA NIH HHS
  • NIMH NIH HHS
  • National Institutes of Health
  • Harvard Brain Science Initiative Bipolar Disorder Seed Grant
  • Baszucki Group ReThink Bipolar Grant

Cite

APA

Cuklanz, K. W., Stein, A., Chouinard, V. A., Ongur, D., & Du, F. (2026). Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development. Science Advances, 12(8). https://doi.org/10.1126/sciadv.aea9014

Vancouver

Cuklanz KW, Stein A, Chouinard VA, Ongur D, Du F. Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development. Science Advances. 2026;12(8). doi:10.1126/sciadv.aea9014

BibTeX
@article{Cuklanz2026,
  author = {Cuklanz, Kyle W and Stein, Abigail and Chouinard, Virginie-Anne and Ongur, Dost and Du, Fei},
  title = {Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {8},
  doi = {10.1126/sciadv.aea9014}
}
Start for free →